Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer

Breast Cancer Res. 2024 Mar 13;26(1):46. doi: 10.1186/s13058-024-01805-w.

Rebecca A Shatsky^{1

2}, Hemali Batra-Sharma^{1

2}, Teresa Helsten^{1

2}, Richard B Schwab^{1

2}, Emily I Pittman¹, Minya Pu¹, Elizabeth Weihe³, Emanuela M Ghia^{1

4}, Laura Z Rassenti^{1

4}, Alfredo Molinolo¹, Betty Cabrera⁵, James B Breitmeyer⁶, George F Widhopf Ii^{2

4}, Karen Messer^{1

7}, Catriona Jamieson^{1

2

5

8}, Thomas J Kipps^{1

4}, Barbara A Parker^{9

10}

¹ Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA.
² Department of Medicine, University of California San Diego, La Jolla, San Diego, CA, USA.
³ Department of Radiology, University of California San Diego, La Jolla, San Diego, CA, USA.
⁴ Center for Novel Therapeutics, University of California San Diego, La Jolla, San Diego, CA, USA.
⁵ University of California San Diego California Institute for Regenerative Medicine Alpha Clinic, La Jolla, San Diego, CA, USA.
⁶ Oncternal Therapeutics, Inc., San Diego, CA, USA.
⁷ Herbert Wertheim School of Public Health, University of California San Diego, La Jolla, San Diego, CA, USA.
⁸ Sanford Stem Cell Institute, University of California San Diego, La Jolla, San Diego, CA, USA.
⁹ Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA, 92093, USA. baparker@health.ucsd.edu.
¹⁰ Department of Medicine, University of California San Diego, La Jolla, San Diego, CA, USA. baparker@health.ucsd.edu.

No abstract available

Publication types